1. Scrip
  2. >>Business
  3. >>Strategy

13 Pharmas Sign Roadmap For Antibiotic Reform – But What Do They Want?

 
• By Lucie Ellis-Taitt

More than 13 global pharma companies, including GlaxoSmithKline, Pfizer and Merck & Co., have agreed a "Roadmap" aimed at relieving the growing antimicrobial resistance crisis worldwide – as well as principles to explore alternative business models and incentives for antibiotic R&D and reimbursement.

Human hands making circle on bright background
Pharmas Collaborate To Seek Resolutions To Global AMR Crisis • Source: Shutterstock/AfricaStudio

This week the UN General Assembly confirmed, in the form of a High-Level Declaration, national, regional and international political commitment to solving the global concern of antibiotic resistance. Following suit, 13 global pharma companies, including GlaxoSmithKline PLC, Pfizer Inc., Merck & Co. Inc. and Sanofi, have agreed a Roadmap for actions they will take to help alleviate the issue.

One key concern for most pharma companies highlighted in the agreement is how to establish new business models that allow...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.